UNSPSC 51351518: Alfasone or algestone or alphasone

This classification denotes a therapeutic progestin with the molecular formula C21H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3JEB53B3WT, chemically known as 16alpha,17-Dihydroxypregn-4-ene-3,20-dione but generally known as algestone, which bears US NIH Compound Identifier 11687. European Medicines Agency schedules Algestone acetophenide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05321MIG. SMILES: CC(=O)C1(C(CC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)O)O.

UNSPSC 51351518 Alfasone or algestone or alphasone is a Commodity code that covers branded and generic steroid pharmaceuticals; state and local governments buy these products through multistate cooperative purchasing agreements that consolidate demand across health systems, correctional facilities, and other public healthcare operations. The scope of work involves manufacturers supplying finished pharmaceutical products with detailed National Drug Codes (NDC), Unique Product Identifiers (UPI), and packaging specifications through authorized drug wholesalers, with compliance requirements including current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and FDA registration. Issuing bodies are primarily state health departments and multistate cooperative purchasing alliances administering contracts on behalf of participating state agencies, counties, cities, and independent healthcare districts; these entities procure through RFPs that establish volume pricing and supply agreements rather than one-time purchases, with awards often structured to allow multiple vendors and price tiers based on therapeutic category and patient safety considerations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the most recent opportunity on January 20, 2026 (RFP S1070000015802 due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating jurisdictions. MMCAP requires vendors to maintain relationships with three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with electronic data interchange capability, and evaluation emphasizes price competitiveness (75 percent) and compliance with administrative fee formats, EDI systems, and the 3 percent administrative fee requirement (20 percent combined). Awarded vendors become effective July 1, 2026, with a two-year contract term and optional extensions, and must maintain comprehensive insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability coverage. No specific dollar values, set-asides, or award caps were disclosed.